Cryo-EM structure of a human cytoplasmic actomyosin complex at near-atomic resolution

Nature

Volumn 534, Issue 7609, 2016, Pages 724-728

  Von Der Ecken, Julian ^a   Heissler, Sarah M ^b,c   Pathan Chhatbar, Salma ^b   Manstein, Dietmar J ^b   Raunser, Stefan ^a  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; MYOSIN ADENOSINE TRIPHOSPHATASE; ACTIN; MYOSIN; PROTEIN BINDING;

CHEMICAL BINDING; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; HYDROPHOBICITY; PROTEIN; SPATIAL RESOLUTION; ULTRASTRUCTURE;

ARTICLE; BONE DISEASE; CARDIAC MUSCLE; CRYOELECTRON MICROSCOPY; CYTOPLASM; CYTOSKELETON; HEARING IMPAIRMENT; HUMAN; HYDROPHOBICITY; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR DYNAMICS; NEMALINE MYOPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; PROTEIN STABILITY; ULTRASTRUCTURE;

ACTINS; ACTOMYOSIN; BINDING SITES; CRYOELECTRON MICROSCOPY; CYTOPLASM; HUMANS; MODELS, MOLECULAR; MYOSINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY;

EID: 85003874425     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18295     Document Type: Article

References (78)

1. Huxley, H. E. The mechanism of muscular contraction. Science 164, 1356-1366 (1969).
2. Heissler, S. M. & Manstein, D. J. Nonmuscle myosin-2: mix and match. Cell. Mol. Life Sci. 70, 1-21 (2013).
3. Lymn, R. W. & Taylor, E. W. Mechanism of adenosine triphosphate hydrolysis by actomyosin. Biochemistry 10, 4617-4624 (1971).
4. Sweeney, H. L. & Houdusse, A. Structural and functional insights into the myosin motor mechanism. Annu. Rev. Biophys. 39, 539-557 (2010).
5. Coureux, P.-D., Sweeney, H. L. & Houdusse, A. Three myosin V structures delineate essential features of chemo-mechanical transduction. EMBO J. 23, 4527-4537 (2004).
6. Gulick, A. M., Bauer, C. B., Thoden, J. B. & Rayment, I. X-ray structures of the MgADP, MgATP? S, and MgAMPPNP complexes of the Dictyostelium discoideum myosin motor domain. Biochemistry 36, 11619-11628 (1997).
7. Llinas, P. et al. How actin initiates the motor activity of myosin. Dev. Cell 33, 401-412 (2015).
8. Lorenz, M. & Holmes, K. C. The actin-myosin interface. Proc. Natl Acad. Sci. USA 107, 12529-12534 (2010).
9. Rayment, I. et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science 261, 58-65 (1993).
10. Behrmann, E. et al. Structure of the rigor actin-tropomyosin-myosin complex. Cell 150, 327-338 (2012).
11. Holmes, K. C., Angert, I., Kull, F. J., Jahn, W. & Schröder, R. R. Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide. Nature 425, 423-427 (2003).
12. von der Ecken, J. et al. Structure of the F-actin-tropomyosin complex. Nature 519, 114-117 (2015).
13. Várkuti, B. H. et al. A novel actin binding site of myosin required for effective muscle contraction. Nature Struct. Mol. Biol. 19, 299-306 (2012).
14. Onishi, H., Mikhailenko, S. V. & Morales, M. F. Toward understanding actin activation of myosin ATPase: the role of myosin surface loops. Proc. Natl Acad. Sci. USA 103, 6136-6141 (2006).
15. Furch, M., Remmel, B., Geeves, M. A. & Manstein, D. J. Stabilization of the actomyosin complex by negative charges on myosin. Biochemistry 39, 11602-11608 (2000).
16. Sasaki, N., Asukagawa, H., Yasuda, R., Hiratsuka, T. & Sutoh, K. Deletion of the myopathy loop of Dictyostelium myosin II and its impact on motor functions. J. Biol. Chem. 274, 37840-37844 (1999).
17. Joel, P. B., Trybus, K. M. & Sweeney, H. L. Two conserved lysines at the 50/20-kDa junction of myosin are necessary for triggering actin activation. J. Biol. Chem. 276, 2998-3003 (2001).
18. Murphy, C. T. & Spudich, J. A. The sequence of the myosin 50-20K loop affects myosin's affinity for actin throughout the actin-myosin ATPase cycle and its maximum ATPase activity. Biochemistry 38, 3785-3792 (1999).
19. Uyeda, T. Q. P., Ruppel, K. M. & Spudich, J. A. Enzymatic activities correlate with chimaeric substitutions at the actin-binding face of myosin. Nature 368, 567-569 (1994).
20. Kojima, S. et al. Functional roles of ionic and hydrophobic surface loops in smooth muscle myosin: their interactions with actin. Biochemistry 40, 657-664 (2001).
21. Milligan, R. A., Whittaker, M. & Safer, D. Molecular structure of F-actin and location of surface binding sites. Nature 348, 217-221 (1990).
22. Van Dijk, J., Furch, M., Lafont, C., Manstein, D. J. & Chaussepied, P. Functional characterization of the secondary actin binding site of myosin II. Biochemistry 38, 15078-15085 (1999).
23. Várkuti, B. H., Yang, Z. & Malnasi-Csizmadia, A. Structural model of weak binding actomyosin in the prepowerstroke state. J. Biol. Chem. 290, 1679-1688 (2015).
24. Cook, R. K., Root, D., Miller, C., Reisler, E. & Rubenstein, P. A. Enhanced stimulation of myosin subfragment 1 ATPase activity by addition of negatively charged residues to the yeast actin NH2 terminus. J. Biol. Chem. 268, 2410-2415 (1993).
25. Miller, C. J., Wong, W. W., Bobkova, E., Rubenstein, P. A. & Reisler, E. Mutational analysis of the role of the N terminus of actin in actomyosin interactions. Comparison with other mutant actins and implications for the cross-bridge cycle. Biochemistry 35, 16557-16565 (1996).
26. Sutoh, K., Ando, M., Sutoh, K. & Toyoshima, Y. Y. Site-directed mutations of Dictyostelium actin: disruption of a negative charge cluster at the N terminus. Proc. Natl Acad. Sci. USA 88, 7711-7714 (1991).
27. Coureux, P.-D. et al. A structural state of the myosin V motor without bound nucleotide. Nature 425, 419-423 (2003).
28. Klein, J. C. et al. Actin-binding cleft closure in myosin II probed by site-directed spin labeling and pulsed EPR. Proc. Natl Acad. Sci. USA 105, 12867-12872 (2008).
29. Sasaki, N., Ohkura, R. & Sutoh, K. Insertion or deletion of a single residue in the strut sequence of Dictyostelium myosin II abolishes strong binding to actin. J. Biol. Chem. 275, 38705-38709 (2000).
30. Muretta, J. M., Rohde, J. A., Johnsrud, D. O., Cornea, S. & Thomas, D. D. Direct real-time detection of the structural and biochemical events in the myosin power stroke. Proc. Natl Acad. Sci. USA 112, 14272-14277 (2015).
31. Müller, M. et al. Functional characterization of the human a -cardiac actin mutations Y166C and M305L involved in hypertrophic cardiomyopathy. Cell. Mol. Life Sci. 69, 3457-3479 (2012).
32. Ohki, T., Ohno, C., Oyama, K., Mikhailenko, S. V. & Ishiwata, S. Purification of cytoplasmic actin by affinity chromatography using the C-terminal half of gelsolin. Biochem. Biophys. Res. Commun. 383, 146-150 (2009).
33. Coulton, A., Lehrer, S. S. & Geeves, M. A. Functional homodimers and heterodimers of recombinant smooth muscle tropomyosin. Biochemistry 45, 12853-12858 (2006).
34. Heissler, S. M. & Manstein, D. J. Comparative kinetic and functional characterization of the motor domains of human nonmuscle myosin-2C isoforms. J. Biol. Chem. 286, 21191-21202 (2011).
35. Li, X. et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nature Methods 10, 584-590 (2013).
36. Mindell, J. A. & Grigorieff, N. Accurate determination of local defocus and specimen tilt in electron microscopy. J. Struct. Biol. 142, 334-347 (2003).
37. Hohn, M. et al. SPARX, a new environment for cryo-EM image processing. J. Struct. Biol. 157, 47-55 (2007).
38. Scheres, S. H. W. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519-530 (2012).
39. Scheres, S. H. W. Beam-induced motion correction for sub-megadalton cryo-EM particles. eLife 3, e03665 (2014).
40. Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
41. Pintilie, G. D., Zhang, J., Goddard, T. D., Chiu, W. & Gossard, D. C. Quantitative analysis of cryo-EM density map segmentation by watershed and scale-space filtering, and fitting of structures by alignment to regions. J. Struct. Biol. 170, 427-438 (2010).
42. Scheres, S. H. W. & Chen, S. Prevention of overfitting in cryo-EM structure determination. Nature Methods 9, 853-854 (2012).
43. Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. Quantifying the local resolution of cryo-EM density maps. Nature Methods 11, 63-65 (2014).
44. Münnich, S., Pathan-Chhatbar, S. & Manstein, D. J. Crystal structure of the rigor-like human non-muscle myosin-2 motor domain. FEBS Lett. 588, 4754-4760 (2014).
45. Šali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993).
46. Lopéz-Blanco, J. R. & Chacón, P. iMODFIT: efficient and robust flexible fitting based on vibrational analysis in internal coordinates. J. Struct. Biol. 184, 261-270 (2013).
47. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011).
48. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
49. Brown, A. et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr. D 71, 136-153 (2015).
50. Nicholls, R. A., Fischer, M., McNicholas, S. & Murshudov, G. N. Conformationindependent structural comparison of macromolecules with ProSMART. Acta Crystallogr. D 70, 2487-2499 (2014).
51. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).
52. Anandakrishnan, R., Aguilar, B. & Onufriev, A. V. H. H+ + 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res. 40, W537-W541 (2012).
53. Hessa, T. et al. Recognition of transmembrane helices by the endoplasmic reticulum translocon. Nature 433, 377-381 (2005).
54. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
55. Stenson, P. D. et al. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 133, 1-9 (2014).
56. UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 43, D204-D212 (2015).
57. Dausse, E. et al. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. J. Clin. Invest. 92, 2807-2813 (1993).
58. Richard, P. et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107, 2227-2232 (2003).
59. Yu, B. et al. Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease. J. Clin. Pathol. 58, 479-485 (2005).
60. Epstein, N. D., Cohn, G. M., Cyran, F. & Fananapazir, L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene. A 908Leu→Val mutation and a 403Arg→Gln mutation. Circulation 86, 345-352 (1992).
61. Geisterfer-Lowrance, A. A. et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell 62, 999-1006 (1990).
62. Blanchard, E., Seidman, C., Seidman, J. G., LeWinter, M. & Maughan, D. Altered crossbridge kinetics in the a MHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ. Res. 84, 475-483 (1999).
63. Cuda, G., Fananapazir, L., Zhu, W. S., Sellers, J. R. & Epstein, N. D. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J. Clin. Invest. 91, 2861-2865 (1993).
64. Woo, A. et al. Mutations of the beta-myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 89, 1179-1185 (2003).
65. Van Driest, S. L. et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44, 602-610 (2004).
66. Mohiddin, S. A. et al. Utility of genetic screening in hypertrophic cardiomyopathy: prevalence and significance of novel and double (homozygous and heterozygous) β -myosin mutations. Genet. Test. 7, 21-27 (2003).
67. Marian, A. J. et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J. Clin. Invest. 104, 1683-1692 (1999).
68. Lankford, E. B., Epstein, N. D., Fananapazir, L. & Sweeney, H. L. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 95, 1409-1414 (1995).
69. Perrot, A. et al. Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Mol. Med. 83, 468-477 (2005).
70. Erdmann, J. et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin. Genet. 64, 339-349 (2003).
71. Moolman, J. C., Brink, P. A. & Corfield, V. A. Identification of a new missense mutation at Arg403, a CpG mutation hotspot, in exon 13 of the β -myosin heavy chain gene in hypertrophic cardiomyopathy. Hum. Mol. Genet. 2, 1731-1732 (1993).
72. Moolman-Smook, J. C., De Lange, W. J., Bruwer, E. C., Brink, P. A. & Corfield, V. A. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am. J. Hum. Genet. 65, 1308-1320 (1999).
73. Greber-Platzer, S. et al. Beta-myosin heavy chain gene mutations and hypertrophic cardiomyopathy in Austrian children. J. Mol. Cell. Cardiol. 33, 141-148 (2001).
74. Villard, E. et al. Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. Eur. Heart J. 26, 794-803 (2005).
75. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
76. Toydemir, R. M. et al. Mutations in embryonic myosin heavy chain (MYH3) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. Nature Genet. 38, 561-565 (2006).
77. Kamisago, M. et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343, 1688-1696 (2000).
78. Daehmlow, S. et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298, 116-120 (2002).